Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and valsartan impact in diabetics pilot trial

Victor L. Serebruany, Alex N. Pokov, D. Aradi, Mehmet Can, James DiNicolantonio, Nodar Kipshidze, Dan Atar

Research output: Contribution to journalArticle

Abstract

Valsartan is known to inhibit platelet activity in both in vitro and ex vivo clinical setting, whereas aliskiren in vitro modulates antithrombin-III in plasma. The authors tested how aliskiren and valsartan combination versus aliskiren monotherapy will affect hemostatic biomarkers in mild-to-moderate hypertensive diabetics in the frame of the Aliskiren and Valsartan Impact in Diabetics (AVID) trial. A total of 52 patients with type 2 diabetes and mild-to-moderate hypertension were equally randomized to aliskiren (150-300 mg/d) and valsartan (160 mg/d) versus aliskiren (150-300 mg/d) alone for 4 weeks. A total of 25 biomarkers were serially measured, of which 16 are related to platelet function, 6 to coagulation, and 3 to fibrinolysis. Aliskiren monotherapy has no significant impact on any of the assessed biomarkers. In contrast, valsartan on top of aliskiren provided significant inhibition of ADP-induced platelet aggregation (P = 0.032), decreased shear-induced activation measured with PFA-100 analyzer (P = 0.041), and diminished expression of GP IIb/IIIa activity (P = 0.027) measured by PAC-1 antibody, GP Ib (CD42b, P = 0.033), vitronectin receptor (CD51/61, P = 0.046), P-selectin (CD62p, P = 0.026), lyso-some-associated membrane protein (CD107a, P = 0.042), and CD40-ligand (CD154, P = 0.048). In AVID trial, valsartan in combination with aliskiren mildly but significantly inhibited platelets, confirming previous observations. In contrast, aliskiren monotherapy does not enhance antithrombin activity, suggesting that previous data probably represent a laboratory artifact. Importantly, these randomized data were generated on top of low-dose daily aspirin, supporting extra benefit for combination use of angiotensin receptor blockers and renin inhibitors in high-risk diabetic population.

Original languageEnglish
Pages (from-to)482-490
Number of pages9
JournalAmerican Journal of Therapeutics
Volume21
Issue number6
Publication statusPublished - Dec 4 2014

Fingerprint

Valsartan
Hemostatics
Biomarkers
Blood Platelets
aliskiren
Integrin alphaVbeta3
Platelet Membrane Glycoprotein IIb
CD40 Ligand

Keywords

  • Aliskiren
  • Clinical trial
  • Diabetes
  • Hemostasis
  • Valsartan

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics : Aliskiren and valsartan impact in diabetics pilot trial. / Serebruany, Victor L.; Pokov, Alex N.; Aradi, D.; Can, Mehmet; DiNicolantonio, James; Kipshidze, Nodar; Atar, Dan.

In: American Journal of Therapeutics, Vol. 21, No. 6, 04.12.2014, p. 482-490.

Research output: Contribution to journalArticle

Serebruany, Victor L. ; Pokov, Alex N. ; Aradi, D. ; Can, Mehmet ; DiNicolantonio, James ; Kipshidze, Nodar ; Atar, Dan. / Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics : Aliskiren and valsartan impact in diabetics pilot trial. In: American Journal of Therapeutics. 2014 ; Vol. 21, No. 6. pp. 482-490.
@article{78192f02cb2348c0bbc6c72791349159,
title = "Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and valsartan impact in diabetics pilot trial",
abstract = "Valsartan is known to inhibit platelet activity in both in vitro and ex vivo clinical setting, whereas aliskiren in vitro modulates antithrombin-III in plasma. The authors tested how aliskiren and valsartan combination versus aliskiren monotherapy will affect hemostatic biomarkers in mild-to-moderate hypertensive diabetics in the frame of the Aliskiren and Valsartan Impact in Diabetics (AVID) trial. A total of 52 patients with type 2 diabetes and mild-to-moderate hypertension were equally randomized to aliskiren (150-300 mg/d) and valsartan (160 mg/d) versus aliskiren (150-300 mg/d) alone for 4 weeks. A total of 25 biomarkers were serially measured, of which 16 are related to platelet function, 6 to coagulation, and 3 to fibrinolysis. Aliskiren monotherapy has no significant impact on any of the assessed biomarkers. In contrast, valsartan on top of aliskiren provided significant inhibition of ADP-induced platelet aggregation (P = 0.032), decreased shear-induced activation measured with PFA-100 analyzer (P = 0.041), and diminished expression of GP IIb/IIIa activity (P = 0.027) measured by PAC-1 antibody, GP Ib (CD42b, P = 0.033), vitronectin receptor (CD51/61, P = 0.046), P-selectin (CD62p, P = 0.026), lyso-some-associated membrane protein (CD107a, P = 0.042), and CD40-ligand (CD154, P = 0.048). In AVID trial, valsartan in combination with aliskiren mildly but significantly inhibited platelets, confirming previous observations. In contrast, aliskiren monotherapy does not enhance antithrombin activity, suggesting that previous data probably represent a laboratory artifact. Importantly, these randomized data were generated on top of low-dose daily aspirin, supporting extra benefit for combination use of angiotensin receptor blockers and renin inhibitors in high-risk diabetic population.",
keywords = "Aliskiren, Clinical trial, Diabetes, Hemostasis, Valsartan",
author = "Serebruany, {Victor L.} and Pokov, {Alex N.} and D. Aradi and Mehmet Can and James DiNicolantonio and Nodar Kipshidze and Dan Atar",
year = "2014",
month = "12",
day = "4",
language = "English",
volume = "21",
pages = "482--490",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics

T2 - Aliskiren and valsartan impact in diabetics pilot trial

AU - Serebruany, Victor L.

AU - Pokov, Alex N.

AU - Aradi, D.

AU - Can, Mehmet

AU - DiNicolantonio, James

AU - Kipshidze, Nodar

AU - Atar, Dan

PY - 2014/12/4

Y1 - 2014/12/4

N2 - Valsartan is known to inhibit platelet activity in both in vitro and ex vivo clinical setting, whereas aliskiren in vitro modulates antithrombin-III in plasma. The authors tested how aliskiren and valsartan combination versus aliskiren monotherapy will affect hemostatic biomarkers in mild-to-moderate hypertensive diabetics in the frame of the Aliskiren and Valsartan Impact in Diabetics (AVID) trial. A total of 52 patients with type 2 diabetes and mild-to-moderate hypertension were equally randomized to aliskiren (150-300 mg/d) and valsartan (160 mg/d) versus aliskiren (150-300 mg/d) alone for 4 weeks. A total of 25 biomarkers were serially measured, of which 16 are related to platelet function, 6 to coagulation, and 3 to fibrinolysis. Aliskiren monotherapy has no significant impact on any of the assessed biomarkers. In contrast, valsartan on top of aliskiren provided significant inhibition of ADP-induced platelet aggregation (P = 0.032), decreased shear-induced activation measured with PFA-100 analyzer (P = 0.041), and diminished expression of GP IIb/IIIa activity (P = 0.027) measured by PAC-1 antibody, GP Ib (CD42b, P = 0.033), vitronectin receptor (CD51/61, P = 0.046), P-selectin (CD62p, P = 0.026), lyso-some-associated membrane protein (CD107a, P = 0.042), and CD40-ligand (CD154, P = 0.048). In AVID trial, valsartan in combination with aliskiren mildly but significantly inhibited platelets, confirming previous observations. In contrast, aliskiren monotherapy does not enhance antithrombin activity, suggesting that previous data probably represent a laboratory artifact. Importantly, these randomized data were generated on top of low-dose daily aspirin, supporting extra benefit for combination use of angiotensin receptor blockers and renin inhibitors in high-risk diabetic population.

AB - Valsartan is known to inhibit platelet activity in both in vitro and ex vivo clinical setting, whereas aliskiren in vitro modulates antithrombin-III in plasma. The authors tested how aliskiren and valsartan combination versus aliskiren monotherapy will affect hemostatic biomarkers in mild-to-moderate hypertensive diabetics in the frame of the Aliskiren and Valsartan Impact in Diabetics (AVID) trial. A total of 52 patients with type 2 diabetes and mild-to-moderate hypertension were equally randomized to aliskiren (150-300 mg/d) and valsartan (160 mg/d) versus aliskiren (150-300 mg/d) alone for 4 weeks. A total of 25 biomarkers were serially measured, of which 16 are related to platelet function, 6 to coagulation, and 3 to fibrinolysis. Aliskiren monotherapy has no significant impact on any of the assessed biomarkers. In contrast, valsartan on top of aliskiren provided significant inhibition of ADP-induced platelet aggregation (P = 0.032), decreased shear-induced activation measured with PFA-100 analyzer (P = 0.041), and diminished expression of GP IIb/IIIa activity (P = 0.027) measured by PAC-1 antibody, GP Ib (CD42b, P = 0.033), vitronectin receptor (CD51/61, P = 0.046), P-selectin (CD62p, P = 0.026), lyso-some-associated membrane protein (CD107a, P = 0.042), and CD40-ligand (CD154, P = 0.048). In AVID trial, valsartan in combination with aliskiren mildly but significantly inhibited platelets, confirming previous observations. In contrast, aliskiren monotherapy does not enhance antithrombin activity, suggesting that previous data probably represent a laboratory artifact. Importantly, these randomized data were generated on top of low-dose daily aspirin, supporting extra benefit for combination use of angiotensin receptor blockers and renin inhibitors in high-risk diabetic population.

KW - Aliskiren

KW - Clinical trial

KW - Diabetes

KW - Hemostasis

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=84914155363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914155363&partnerID=8YFLogxK

M3 - Article

C2 - 23698186

AN - SCOPUS:84914155363

VL - 21

SP - 482

EP - 490

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 6

ER -